Cemiplimab for maintenance in adrenocortical cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adrenocortical cancer (ACC).
- You have finished 4-6 cycles of EDP-M chemotherapy (and possibly had surgery) and your disease has not gotten worse.
- You are able to take care of yourself, at least up to being out of bed more than half the day.
- You have adequate blood counts, kidney function, and liver function as measured by standard lab tests.
- You have not had certain types of immunotherapy before, or an autoimmune disease requiring steroids.
- If you are able to have children, you agree to use effective contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (cemiplimab and OSE2101) as ongoing treatment after initial chemo-immunotherapy for advanced lung cancer. It is for patients whose tumor DNA is still detectable in the blood, and who carry a specific immune marker called HLA-A2.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests whether a drug called cemiplimab (an immunotherapy that helps your immune system fight cancer) can keep penile cancer from growing after you've finished your first round of chemotherapy. Participants will either get cemiplimab as a maintenance treatment or standard supportive care to see which helps better.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests whether continuing treatment with cemiplimab (an immunotherapy drug) after initial chemotherapy can help keep vulvar cancer from growing, compared to standard supportive care. It is for people whose cancer is stable or improved after their first round of chemotherapy.
Hear when a new Adrenal Cortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.